Diagnostic Testing
Page 1 • 3 itemsGain critical insights into global diagnostic testing market trends, regulatory updates, and innovation impacting pharma BD and investment strategies.
FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
Guardant Health receives FDA approval for blood-based companion diagnostic to identify patients eligible for VEPPANU treatment in advanced breast cancer with ESR1 mutations.
FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
Guardant Health receives FDA approval for Guardant360 CDx liquid biopsy test as companion diagnostic for VEPPANU (vepdegestrant) in advanced breast cancer patients.
Labcorp Launches FDA-Approved PD-L1 Companion Diagnostic for KEYTRUDA Ovarian Cancer Treatment
Labcorp launches nationwide availability of FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic to identify ovarian cancer patients eligible for KEYTRUDA treatment.